Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: Its relationship with vimentin and p53 protein

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 147-154

  Domagala, Wenancjusz ^a   Markiewski, Maciej ^a   Harezga, Barbara ^b   Dukowicz, Andrzej ^b   Osborn, Mary ^c  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY MIB 1; MONOCLONAL ANTIBODY; PROTEIN P53; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL DIVISION; FEMALE; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; VIMENTIN;

EID: 0030060718     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Adair, F., Berg, J., Joubert, L., and Robbins, G. F. Long-term follow up of breast cancer patients: the 30-year report. Cancer (Phila.), 33: 1145-1150, 1974.
2. DeVita, V. T., Hellman, S., and Rosenberg, S. A. Cancer Principles and Practice of Oncology. Philadelphia: J. B. Lippincott Co., 1989.
3. Silvestrini, R., Daidone, M. G., and Gasparini, G. Cell cycle kinetics as a prognostic marker in node-negative breast cancer. Cancer (Phila.), 56: 1982-1987, 1985.
4. Tubiana, M., Pejovic, M. H., Chavaudra, N., Contesso, G., and Malaise, E. P. The long-term prognostic significance of the thymidine labelling index in breast cancer. Int. J. Cancer, 33: 441-445, 1984.
5. Kallioniemi, O. P., Hietanen, T., Mattila, J., Lehtinen, M., Lauslahti, K., and Koivula, T. Aneuploid DNA content and high S phase fraction of tumour cells are related to poor prognosis in patients with primary breast cancer. Eur J. Cancer & Clin. Oncol., 23: 277-282, 1987.
6. Laroye, G. J., and Minkin, S. The impact of mitotic index on predicting outcome in breast carcinoma: a comparison of different counting methods in patients with different lymph node status. Mod. Pathol., 4: 456-460, 1991.
7. Bouzubar, N., Walker, K. J., Griffiths, K., Ellis, I. O., Elston, C. W., Robertson, J. F. R., Blamey, W. W., and Nicholson, R. I. Ki-67 immunostaining in primary breast cancer: pathological and clinical associations. Br. J. Cancer, 59: 943-947, 1989.
8. Gaglia, P., Bernadi, A., Venesio, T., Caldarola, B., Lauro, D., Cappa, A. P., Calderini, P., and Liscia, D. S. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur. J. Cancer, 29A: 1509-1513, 1993.
9. Gasparini, G., Bevilacqua, P., Pozza, F., Meli, S., Boracchi, P., Marubini, E., and Sainsbury, J. R. C. Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br. J. Cancer, 66: 970-976, 1992.
10. Railo, M., Nordling, S., von Boguslawsky, K., Leivonen, M., Kyllönen, L., and von Smitten, K. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br. J. Cancer, 68: 579-583, 1993.
11. Sahin, A. A., Ro, J., Ro, J. Y., Blick, M. B., el-Naggar, A. K., Ordonez, N. G., Fritsche, H. A., Smith, T. L., Hortobagyi, G. N., and Ayala, A. G. Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (Phila.), 68: 549-557, 1991.
12. Wintzer, H. O., Zipfel, I., Schulte-Möntung, J., Hellerich, U., and von Kleist, S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer (Phila.), 67: 421-428, 1991.
13. Domagala, W., Lasota, J., Bartkowiak, J., Weber, K., and Osborn, M. Vimentin is preferentially expressed in human breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am. J. Pathol., 136: 219-227, 1990.
14. Raymond, W., and Leong, A-Y. Vimentin - a new prognostic parameter in breast carcinoma? J. Pathol., 158: 107-114, 1989.
15. Cattoretti, G., Rilke, F., Andreola, S., and D'Amato, D. P53 expression in breast cancer. Int. J. Cancer, 41: 178-183, 1988.
16. Isola, J., Visakorpi, T , Holli, K., and Kallioniemi, O-P. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J. Natl. Cancer Inst., 84: 1109-1114, 1992.
17. Allred, D., Clark, G., Elledge, R., Fuqua, S., Brown, R., Chamness, G., Osborne, C., and McGuire, W. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J. Natl. Cancer Inst., 85: 200-206, 1993.
18. Domagala, W., Lasota, I., Dukowicz, A., Markiewski, M., Striker, G., Weber, K., and Osborn, M. Vimentin expression appears to be associated with poor prognosis in node-negative ductal NOS breast carcinomas. Am J Pathol., 137: 1299-1304, 1990.
19. Domagala, W., Striker, G., Szadowska, A., Dukowicz, A., Harezga, B., and Osborn, M. p53 protein and vimentin in invasive ductal NOS breast carcinoma-relationship with survival and sites of metastases. Eur. J. Cancer, 30A: 1527-1534, 1994.
20. Russo, A., Bazan, V., Morello, V., Tralongo, V., Nagar, C., Nuara, R., Dardanoni, G., Bazan, P., and Tomasino, R. M. Vimentin expression, proliferating cell nuclear antigen and flow cytometric factors. Prognostic role in breast cancer. Anal. Quant. Cytol. Histol., 16: 365-174, 1994.
21. Thor, A., Moore, D. L. Edgerton, S., Kawasaki, E., Reihsaus, E., Lynch, H., Marcus, J., Schwartz, L., Chen, L-C., Mayall, B., and Smith, H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J. Natl. Cancer Inst., 84: 845-855, 1992.
22. Cattoretti, G., Becker, M. H. G., Key, G., Duchrow, M., Schlüter, C., Galle, J., and Gerdes, J. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol., 168: 357-363, 1992.
23. Gerdes, J., Lemke, H., Baisch, H., Wacher, H. H., Schwab, U., and Stein, H. Cell cycle analysis of a cell proliferation-associated nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol., 133: 1710-1715, 1984.
24. Barbareschi, M., Girlando, S., Mauri, F. M., Forti, S., Eccher, C., Mauri, F. A., Togni, R., Palma, P., and Doglioni, C. Quantitative growth fraction evaluation MIB1 and Ki-67 antibodies in breast carcinomas. Am. J. Clin. Pathol., 102: 171-175, 1994.
25. Weidner, N., Moore, D. H., II, and Vartanian, R. Correlation of Ki-67 antigen expression with mitotic figure index and tumor grade in breast carcinomas using the novel "paraffin"-reactive MIB1 antibody. Hum. Pathol., 25: 337-342, 1994.
26. Thompson, E., Soonmyoung, P., Brunner, N., Sommers, C., Zugmaier, G., Clarke, R., Shima, T., Torri, J., Donahue, S., Lippman, M., Martin, G., and Dickson, R. B. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol., 150: 534-544, 1992.
27. Millis, R., and Girling, A. The breast. In: S. S. Sternberg (ed.), Diagnostic Surgical Pathology, pp. 253-313. New York: Raven Press, Ltd., 1989.
28. Bloom, H., and Richardson, W. Histologic grading and prognosis in breast cancer. Br. J. Cancer, 11: 359-377, 1957.
29. Rajakariar, R., and Walker, R A. Pathological and biological features of mamographically detected invasive breast carcinomas. Br. J. Cancer, 71: 150-154, 1995.
30. Gerdes, J., Lellé, R. J., Pickartz, H., Heidenreich, W., Schwarting, R., Kurtsiefer, L., Stauch, G., and Stein, H. Growth fractions in breast cancers determined in situ with monoclonal antibody Ki-67. J. Clin. Pathol., 39: 977-980, 1986.
31. McGurrin, J. F., Doria, M. I., Dawson, P. J., Karrison, T., Stein, H. O., and Franklin, W. A. Assessment of tumor cell kinetics by immunohistochemistry in carcinoma of breast. Cancer (Phila.), 59: 1744-1750, 1987.
32. Wrba, F., Chott, F., Reiner, A., Reiner, G., Markis-Ritzinger, E., and Holzner, J. H. Ki-67 immunoreactivity in breast carcinomas in relation to transferrin receptor expression, estrogen receptor status and morphological criteria. An immunohistochemical study. Oncology (Basel), 46: 255-259, 1989.
33. Veronese, S. M., Gambacorta, M., Gottardi, O., Scanzi, F., Ferrari, M., and Lampertico, P. Proliferation index as a prognostic marker in breast cancer. Cancer (Phila.), 71: 3926-3931, 1993.
34. Locker, A. P., Birrell, K., Bell, J. A., Nicholson, R. I., Elston. C. W., Blamey, W. R., and Ellis, I. O. Ki-67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur. J. Surg. Oncol., 18: 224-229, 1992.
35. Weikel, W., Beck, T., Mitze, M., and Knapstein, P. G. Immunohistochemical evaluation of growth fraction in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res. Treat., 18: 149-154, 1991.
36. Kreipe, H., Alm, P., Olsson, H., Hauberg, M., Fischer, L., and Parwaresch, R. Prognostic significance of a formalin-resistant nuclear proliferation antigen in mammary carcinomas as determined by the monoclonal antibody Ki-Sl. Am. J. Pathol., 142: 651-657, 1993.
37. Pinder, S. E., Wencyk, P., Sibbering, D. M., Bell, J. A., Elston, C. W., Nicholson, R., Robertson, J. F. R., Blamey, R. W., and Ellis, I. O. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis-associations with other prognostic factors and survival. Br. J. Cancer. 71: 146-149, 1995.
38. Toi, M., Osaki, Y., Yamada, H., and Toge, T. Epidermal growth factor receptor expression as a prognostic indicator in breast cancer. Eur. J. Cancer. 27: 977-980, 1991.
39. Bosari, S., Lee, A. K. C., Viale, G., Heatley, G. J., and Coggi, G. Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with Song-term follow-up. Virchows Arch. A. Pathol. Anat. Hist., 421: 291-295, 1992.
40. Lipponen, P., Aaltomaa, S., Syrjänen, S., and Syrjanen, K. p53 protein expression in breast cancer as related to histopathological characteristics and prognosis. Int. J. Cancer, 55: 51-56, 1994.
41. Caleffi, M., Teague, M. W., Jensen, R. A., Vnencak-Jones, C. L., Dupont, D., and Parl, F. F. p53 gene mutations and steroid receptor in breast cancer. Cancer (Phila.), 73: 2147-2156, 1994.
42. Hsiao, M., Low, J., Dorn, E., Ku, D., Pattengale, P., Yeargin, J., and Haas, M. Gain-of-function mutations of the p53 gene induce lymphohematopoietie metastatic potential and tissue invasiveness. Am. J. Pathol., 145, 702-714, 1994.
43. Tomasino, R. M., Russo, A., Bazan, V., Morello, V., Tralongo, V., Nagar, C., Salvato, M., Taormina, P., Marrazzo, A., and Nuara, R. Evaluation of integrated morpho-biological indicators in breast cancer. In Vivo (Athens). 7: 601-605, 1993.
44. Thompson, E. W , Torri, J., Sabol, M., Sommers, C. L., Byers, S. W., Valverius, E. M., Martin, G. R., Lippman, M. E., Stampfer, M. R., and Dickson, R. B. Oncogene-induced basement membrane invasiveness in human mammary epithelial cells. Clin. & Exp. Metastasis, 12: 181-194, 1994
45. Sommers, C. L., Thompson, E. W., Tom, J. A., Kemler, R., Gelm, E. P., and Byers, S. W. Cell adhesion molecule uvormorulin expression in human breast cancer cell lines: relationship to morphology and invasive capacities. Cell Growth & Differ., 2: 365-372, 1991.
46. Stover, D. M., Carey, I., Garzon, R. I., and Zehner, Z. E. A negative regulatory factor is missing in human metastatic breast cancer cell line Cancer Res , 54. 3092-3095, 1994.
47. Azzam, H. S., Arand, G., Lippman, M. E., and Thompson, E. W. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independent of MMP-2 production. J. NtUt. Cancer Inst., 85: 1758-1765 1993.
48. Sommers, C. L., Walker-Jones, D., Heckford, S. E., Worland, P., Valverius, E., Clark, R., McCormick, F., Stampfer, M., Abularach, S., and Gelmann, E. P. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res., 49. 4258-4263, 1989.